Chief Scientific Officer

Dr. Carlo Boutton joined Biotalys in May 2022 as Chief Scientific Officer. Carlo brings more than 20 years of antibody and biochemistry leadership to the company. In his most recent role as Sanofi’s Global Head of Innovation, Large Molecules Research, Carlo drove the innovation strategy and managed an expansive team exploring novel technologies with antibodies, NANOBODIES® and other biologic modalities to find innovative pharmaceutical solutions. Before Sanofi, he held various scientific leadership roles at Ablynx (now Sanofi), where he focused on bioinformatics, protein modelling and finding new therapeutic applications for its NANOBODY® platform. At Ablynx, Carlo was also involved in multiple strategic partnerships as member of Joint Steering Committees. Previously, he took part in several anti-HIV and anti-HCV drug discovery projects at Tibotec (a subsidiary of Johnson & Johnson). At the start of his career, he contributed to the development of a platform to develop rationally designed therapeutics in the broad field of immunotherapy, at Algonomics (now Lonza). He is named co-inventor on more than 20 patent applications.

Carlo Boutton obtained his M.S. and PhD from the University of Leuven (Belgium), where he researched the physico-chemical behavior of proteins under high-electromagnetic fields.